EGFR and head and neck squamous cell carcinoma: A phase II trial of lapatinib (1500 mg o.d.)in recurrent/metastastic SCCHN reported no objective responses, suggesting little activity in either EGFR inhibitor naïve or refractory patients (Abidoye et al, 2006) (Table 3).